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ABSTRACT
The identification of chromosomal aberrations in prostate cancer has been widely studied with several known oncogenes 
and tumor suppressor genes have successfully been discovered. The most frequent aberrations detected in western 
population were losses in chromosome 5q, 6q, 8p, 13q, 16q, 17p, 18q and gains of 7p/q and 8q. The purpose of this 
study was to determine the chromosomal aberrations among Malaysian men of Southeast Asia population and discover 
those potential genes within that chromosomal aberrant region. Thirty-six formalin-fixed paraffin embedded specimens 
consist of eight organ-confined prostate cancer cases, five with capsular invasion, 14 showed metastasis and nine cases 
had no tumor stage recorded, were analyzed by array CGH technique. Chromosomal losses were frequently detected at 
4q, 6q, 8p, 13q, 18q while gains at 7q, 11q, 12p, 16q and 17q. Gain of 16q24.3 was statistically significant with tumor 
size. Gains of 6q25.1 and Xq12 as well as losses of 3p13-p1.2 and 13q33.1-q33.3 were significantly correlated with 
Gleason grade whereas 12p13.31 gain was associated with bone metastasis. Several potential genes have also been 
found within that aberrant region which is myopodin (4q26-q27), ROBO1 (3p13-p11.2), ERCC5 (13q33.1-q33.3) and CD9 
(12p13.31), suggesting that these genes may play a role in prostate cancer progression. The chromosomal aberrations 
identified by array CGH analysis could provide important clues to discover potential genes associated with prostate 
tumorigenesis of Malaysian men.
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ABSTRAK
Pengenalpastian aberasi kromosom dalam kanser prostat telah dikaji secara meluas dengan beberapa onkogen dan 
gen penindas tumor telah berjaya ditemui. Aberasi kromosom yang paling kerap dikesan dalam kalangan penduduk 
barat ialah delesi pada kromosom 5q, 6q, 8p, 13q, 16q, 17p, 18q dan amplifikasi pada kromosom 7p/q dan 8q. Tujuan 
kajian ini adalah untuk menentukan aberasi kromosom dalam kalangan lelaki Malaysia di Asia Tenggara dan seterusnya 
mengenal pasti gen berpotensi yang terkandung dalam kawasan kromosom yang mengalami aberasi. Sejumlah 36 blok tisu 
spesimen kanser prostat yang diawet formalin dan terbenam dalam lilin parafin, digunakan dalam kajian ini yang terdiri 
daripada 8 kes organ-terbatas kanser prostat, 5 kes dengan kapsular invasif, 14 kes menunjukkan metastasis manakala 
9 kes tiada rekod peringkat tumor. Sampel dianalisis oleh teknik penghibridan perbandingan genomik tatasusunan. 
Delesi kromosom lebih kerap dikesan pada 5q, 6q, 8p, 13q, 18q manakala amplifikasi pada 7q, 11q, 12p, 16q dan 17q. 
Amplifikasi 16q24.3 menunjukkan hubungan yang signifikan dengan saiz tumor. Amplifikasi 6q25.1 dan Xq12 serta delesi 
3p13-p1.2 dan 13q33.1-q33.3 adalah signifikan dengan gred tumor manakala amplifikasi 12p13.31 adalah signifikan 
dengan metastasis ke bahagian tulang. Beberapa gen yang berpotensi juga telah ditemui di dalam kawasan aberasi 
berkenaan termasuklah gen myopodin (4q26-S27), ROBO1 (3p13-p11.2), ERCC5 (13q33.1-q33.3) dan CD9 (12p13.31) 
yang berkemungkinan berperanan penting dalam perkembangan kanser prostat. Aberasi kromosom yang dikesan oleh 
teknik tatasusunan CGH memberi petunjuk penting terhadap penemuan gen berpotensi yang berkemungkinan terlibat 
dalam tumorigenesis prostat pesakit Malaysia.
Kata kunci: Aberasi kromosom; gen yang berkemungkinan; kanser prostat; tatasusunan CGH
INTRODUCTION
Prostate cancer remains one of the most common 
malignancies afflicting men today. A total of 914000 new 
cases were reported in 2008, making it the second most 
frequently diagnosed cancer in the world. It accounted for 
about 6.1% of all male cancer deaths in 2008, with close 
to three-quarters of the cases occur in developed countries 
(Ferlay et al. 2010). The incidence rates of prostate cancer 
vary widely across the world. The rates are relatively high 
in western countries such as US, Canada and Australia but 
lowest in Asian countries such as China and other parts of 
Asia. In Malaysia, prostate cancer ranked the fourth most 
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frequent cancer in males and accounted for 6.2% of the 
total cancer cases with an age standardized incidence rate 
(ASR) of 6.2 per 100000 population (Zainal & Nor Saleha 
2011). Among the ethnic groups, Chinese recorded the 
highest incidence, followed by Malays and Indians (Zainal 
& Nor Saleha 2011).
 It has been shown that chromosomal alteration 
is a common event in cancer (Lengauer et al. 1998). 
Chromosomal alterations include translocation, 
amplification, rearrangements, deletion and mutation 
usually affect many important genes involved in cell cycle 
regulation, apoptosis, signal transduction and DNA repair 
(Diamandis 1997; Fearon & Vogelstein 1990; Gelmann 
2008). These affected genes are classified as oncogenes 
and tumor suppressor genes. Like other solid tumors, the 
prostate tumorigenesis involves multiple genetic alterations 
across the genome.
 The identification of chromosomal alterations is 
important in discovering genes which may play a role 
in prostate tumorigenesis. The emergence of molecular 
technique such as comparative genomic hybridization 
(CGH) since the mid-1990s followed by the more recent 
technology; array comparative genomic hybridization 
(array CGH) and DNA microarray in the past few years, 
have helped to identify some critical genetic aberrations 
in prostate cancer. Array CGH was first introduced by 
Solinas-Toldo et al. (1997) and it demonstrated higher 
sensitivity for detection of DNA copy number changes that 
are either gain or loss in specific chromosomal region of 
tumor samples.
 Previous studies had applied these platforms to screen 
for the chromosomal changes in prostate cancer cases. The 
most common chromosomal alterations identified using 
CGH and array CGH in early stage clinical prostate cancer 
are losses in 5q, 6q, 8p, 13q, 16q, 17p, and 18q and gains 
of 7p/q and 8q (Paris et al. 2004; van Dekken et al. 2004; 
Visakorpi et al. 1997). Furthermore, there were multiple 
frequent altered regions of losses detected at 2q21-22, 
5q13-21, 6q14-21, 8p21-23, 10q23-25, 13q14-22, 16q13-
24, 18q12-23 and 21q22 as well as gain of 3q23-33, 
7q21-33, 8q12-23, 17q24-25, and Xq11-23 (Fu et al. 2000; 
Kasahara et al. 2002; Nupponen et al. 1998). In addition to 
that, previous array CGH studies had identified several novel 
recurrent copy number aberrations of chromosomal gains at 
2p25, 9p13-21, 11p15.4, 16p13.3 and 16p12.2-p11.2 (Paris 
et al. 2004; Ribeiro et al. 2006; Saramaki et al. 2006). The 
chromosomal aberrations study of prostate cancer has led 
to the identification of several important tumor suppressor 
genes and oncogenes. Some examples include NKX3-1 (8p 
loss), PTEN and MXI1 (10q loss), FOXO1A (13q loss), EZH2 
and MCM7 (7q gain), MYC (8q gain) and the androgen 
receptor (AR) gene at Xq12. 
 The chromosomal alterations involved in the 
development and progression of prostate cancer among 
Malaysian men of Southeast Asia population is yet 
unknown. In order to gain new insights into the genetic 
changes involved in prostate cancer of Malaysian male, 
we therefore attempt to determine the chromosomal 
aberrations and characterize those potential genes involved 
in prostate cancer progression in our patients. We applied 
array CGH to formalin-fixed paraffin embedded (FFPE) 
tumor blocks of patients at various stages of prostatic 
tumor development. The array CGH profiles were then 
correlated with clinicopathological parameters (age, tumor 
size, Gleason grade and tumor stage).
MATERIALS & METHODS
SPECIMEN
Tumor specimens consisted of 36 formalin-fixed paraffin-
embedded (FFPE) prostate carcinomas obtained between 
year 1998 and 2008. Of 36 cases, eight were organ-
confined prostate cancer, five were prostate cancer with 
capsular invasion), 14 showed metastasis while nine 
cases had no tumor stage recorded. All specimens were 
adenocarcinomas, taken from patients who underwent 
transurethral resections or orchidectomies at Universiti 
Kebangsaan Malaysia Medical Centre (UKMMC). The 
patients comprised of 29 (81%) Malays, 6 (17%) Chinese 
and 1 (3%) were of other races. The age of these patients 
ranged between 60 and 88, with the mean age at diagnosis 
was 70.5 years (median 72). The tumors were graded 
according to the Gleason grading system (Gleason, 1992) 
and staged according to the TNM classification. The mean 
tumor Gleason score was G7 (range G5 to G10). The 
presence of tumor area on hematoxylin and eosin (H&E) 
was verified by a pathologist.
DNA EXTRACTION
DNA from FFPE samples was isolated according to 
manufacturer’s recommended procedure and is based on 
the method previously described (van Beers et al. 2006). 
Briefly, the FFPE tumor blocks were sliced into 4-6 slices 
of 20 μm thickness and placed in 1.5 mL eppendorf tube. 
Sections were heat deparaffinated in 480 μL PBS and 20 
μL 10% Tween 20 at 90°C for 10 min and immediately 
placed on ice for 2 min. Wax disc were remove with a 
tweezer. Tissues were incubated overnight in 1 M NaSCN 
to remove crosslink, followed by proteinase-K (20 mg/
mL stock) treatment at 55°C at 450 rpm (Eppendorf® 
Thermomixer) to digest the tissues. Two more aliquots of 
40 μL proteinase-K were added at 6 and 10 h. Following 
two days of proteinase-K treatment, DNA extraction was 
continued using the DNeasy tissue extraction kit (Qiagen). 
The genomic DNA (gDNA) concentration was quantitated 
with Nanodrop UV-VIS Spectrophotometer (Agilent, US) 
and gel electrophoresis. Normal commercial genomic 
DNA (Human Male Genomic DNA, Promega) was used as 
reference sample. Reference sample were heat fragmented 
at 95°C until its median fragment length was similar to that 
of the test samples. 
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ARRAY COMPARATIVE GENOMIC HYBRIDIZATION 
(ARRAY CGH) 
Array CGH was performed according to manufacturer’s 
instructions (Agilents Technologies, USA). Briefly, tumor 
DNA (0.5 μg) and normal male reference DNA (0.5 μg) 
were labeled with ULS-Cy5 and ULS-Cy3 respectively 
before incubated at 85°C for 30 min. Labeled gDNA was 
then purified using Agilent-KREApureTM columns (Agilent 
Technologies, USA) for unbound dye removal. The Cy5- 
and Cy3-labeled gDNA were combined and mixed with 5 
μL of Human Cot-1 DNA (Invitrogen), 11 μL of Agilent 
10X CGH Blocking Agent and 55 μL of Agilent 2X CGH 
hybridization buffer before denatured at 95°C for 3 min 
and incubated at 37°C for 30 min. Agilent CGHblock 
was then added and the hybridization mixtures were 
hybridized to the Agilent Human Genome CGH 4 X 44K 
Microarray slide. The 4X 44K slide contains four identical 
arrays consisting of ~43,000 in situ synthesized 60-mer 
oligonucleotide probes that represented the coding and 
non-coding sequences. The hybridization was carried out 
in an Agilent SureHyb chamber in a rotator oven at 65oC 
for 40 h. Three washing steps were done; room temperature 
with Agilent’s Oligo CGH Wash buffer 1 for 5 min, a 37°C 
wash with Agilent’s Oligo CGH Wash buffer 2 for 1 min 
and an acetonitrile rinsed at room temperature for 1 min. 
ARRAY CGH IMAGING AND DATA ANALYSIS
The slides were scanned on an Agilent DNA Microarray 
Scanner. Scanned images were analyzed using Feature 
Extraction software (version 9.5) and then imported into 
Agilent Genomic DNA Workbench software (version 5.0) 
for analysis. Chromosomal aberrations were considered as 
gains when the log2 ratio was higher than 0.25 and as loss 
when the ratio was below -0.25. The aberration detection 
module-1 (ADM-1), an aberration detection algorithm from 
Agilent’s DNA Genomic Workbench software was used to 
identify regions of copy number gains or losses.
STATISTICAL ANALYZES
The correlation between chromosomal aberrant regions 
and the clinicopathological parameters (tumor size, 
Gleason grade, TNM cancer stage and metastasis status) 
were performed using Chi-square test whereas the Fisher’s 
Exact test was used when appropriate. The p-value of <0.05 
was considered to be significant.
RESULTS
GENETIC CHANGES IN PROSTATE CARCINOMA CASES
Chromosomal aberrations were detected in all 36 prostate 
cancer cases with multiple aberrations including both gains 
and losses of chromosomal materials (Figure 1). The mean 
aberrations were 43.2 per tumor (range, 1 to 85). There 
were 54.2% cases showed chromosomal losses whereas 
45.8% cases displayed gains. Chromosomal losses tend 
to be more frequent than gains in the majority of cases. 
The mean number of losses was 23.4 per tumor (range, 1 
to 59) and of gains were 20.7 per tumor (range, 1 to 50).
 The most frequent chromosomal aberrations in 
all 36 cases were losses on chromosome 4q (75%), 6q 
(74%), 8p (61.1), 13q (69.4%) and 18q (52.8%) while 
gains were encountered most frequently at 7q (52.8%), 
11q (72.2%), 12p (75%), 16q (52.8%) and 17q (86.1%). 
Losses of chromosome arms 4p, 8p, 18q, 19q and gains 
of 8q, 11q, 17q and Xq were commonly shared between 
organ-confined prostate cancer cases, prostate cancer 
with capsular invasion and metastatic cases. We also 
detected the gain of 8q at four independent regions at 
lower frequency which were 8q23.3-q24.1 (27.8%), 
8q24.2 (25%), 8q21.1 (22.2%) and 8q24.3 (22.2%). The 
clinicopathological data obtained from 36 prostate cancer 
patients and genetic aberrations are summarized in Table 
1. Table 2 depicts the chromosomal aberrations detected 
in each ethnic group. Loss at 4q25 and gains at 17q12 and 
Xq12 were the frequent aberrant regions shared by each 
group. All regions of gains and losses in these 3 ethnic 
groups were correlated with clinicopathological data, 
however no statistical differences were found (data not 
shown).
 Loss at chromosomal region 4q26-q27 (75.0%) was 
the most frequent aberration found in this study. Genes 
identified at these aberrant chromosomal regions were 
SYNPO2 (4q26-q27). Loss of 4q26-q27 were found in 29.6% 
of organ-confined prostate cancer cases, 7.4% in capsular 
invasion and 37.0% in metastasis. Table 3 highlighted the 
most common chromosomal aberrant regions of losses 
detected in all 36 cases together together with the genes 
involved within the aberrant regions. Amplification of 
chromosomal region 17q12 (86.1%) were the most 
frequent aberration found in this study. One of the genes 
identified within this aberrant chromosomal region was 
HER2 (17q12). HER2 amplified region was found in 25.8% of 
organ-confined prostate cancer, 16.1% of capsular invasion 
and 35.5% in metastasis. The most common chromosomal 
aberrant regions of gains in all 36 cases and the genes 
located within the aberrant regions are summarized in 
Table 4. 
 Array CGH analysis detected several genes known to 
be established in prostate cancer as well as other potential 
genes which have not been described. Chromosomal 
losses contain genes such as ROBO1 (3p13-p11.2), 
SYNPO2 (4q26-q27), MAP3K7 (6q15-q16.1), MSR1 (8p22), 
NKX3-1 (8p21.2), PTEN (10q23.2-q23.31), CCND2 
(12p13.33-p13.31), ERCC5 (13q33.1), bcl2 (18q11.2-q23) 
and ELAC2 (13q14.2) while gains contain genes such 
as EZH2 (7q36.1), TRPS1 (8q23.3-q24.1), MYC (8q24.2), 
PSCA (8q21.1), TCEB1 (8q24.3), CCND1 (11q13.1), CD9 
(12p13.31), CDK10 (16q24.3), HER2 (17q12) and AR (Xq12). 
 The correlation between chromosomal aberrations 
and clinicopathological parameter (tumor size, Gleason 
grade and metastasis) were evaluated and summarized in 
Table 5. Gain of 16q24.3 showed correlation with tumor 
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FIGURE 1. Chromosomal aberrations of 36 prostate tumors. Gains and losses are shown as red and green bars, respectively, 
representing the overall chromosomal changes observed in all cases
size >4.5 cm (p=0.023). Losses of 3p13-p11.2 (p=0.044) 
and 13q33.1 (0.017) and gains at 6q25.1 (0.019) and 
Xq12 (0.044) were correlated significantly with high 
Gleason grade (>Gleason 7). The 12p13.31 gain correlated 
significantly with bone metastases (p=0.043). 12p13.31 
gain was also found in 25.9% of organ-confined prostate 
cancer and 11.1% cases with capsular invasion. 
DISCUSSION
This array CGH study represents the first genome-wide 
screening of chromosomal aberrations in prostate cancer 
of Malaysian men. Losses of 4q, 6q 8p, 13q and 18q as 
well as gains of 7q, 11q, 12p, 16q and 17q appeared to 
be the most common aberrations found in our cases. The 
overall genomic profile and the chromosomal aberrant 
regions identified in prostate cancer of Malaysian men 
seem in accordance with previously reported in western 
populations. However, in our study the gain of 8q was 
found at lower frequency than that of previously reported. 
We have also found minimal overlapping regions at several 
chromosomal sites, containing several established tumor 
suppressor genes and oncogenes such as HER2, AR, MYC, 
BIN1, MAP3K7 as well as potential genes such as myopodin, 
ERCC5, CD9, ROBO1 and CDK10. Furthermore, we detected 
several aberrant regions which showed significant 
correlation with tumor size, high tumor grade and bone 
metastasis. Such aberrations include losses of 3p13-p11.2, 
4q26-q27 and 13q33.1-q33.3 as well as gains of 6q25.1, 
12p13.31, 16q24.3, 17q12 and Xq12.
CHROMOSOMAL LOSSES
Chromosomal region 4q26-27 was the most frequent 
losses found in our study. This region includes SYNPO2 
gene, that also known as myopodin. Myopodin is an actin-
bundling protein, the second member of the synaptopodin 
protein family (Weins et al. 2001). Myopodin is 
normally expressed in neurons and podocytes however 
its expression has also been detected in colon, uterus, 
stomach, lung, small intestine and kidney (Lin et al. 2001; 
Weins et al. 2001). Loss of myopodin expression has been 
previously observed in prostate cancer cases, and it has 
been shown to suppress tumor growth and metastasis in 
several prostate cancer cell lines in vitro (Jing et al. 2004). 
Previous analysis also demonstrated the tumor suppressor 
activity of myopodin in bladder cancer, and suggested that 
loss of nuclear myopodin expression can be a predictive 
value of clinical outcome for patients with progressive 
bladder cancer (Sanchez-Carbayo et al. 2003). The 
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TABLE 1. Clinicopathological data of 36 prostate adenocarcinoma and the most frequent genetic aberrations in all cases
Case Tumour 
size
Gleason 
score
TNM Most frequent aberrant regions
Organ-confined prostate cancer
S1
S2
S3
S4
S5
S6
S7
S8
0.0
4.0
6.0
4.5
3.0
2.5
4.0
6.0
5 (3+2)
8(3+5)
7(3+4)
8 (4+4)
8 (4+4)
9 (5+4)
6 (3+3)
5 (3+2)
T2N0M0
T2N0M1
T1NXM0
T2N0M0
T2N0M0
T2N0M0
T1N0M0
T2N0M0
Gains:
1q32.1, 3p21.31-p21.1, 7p22.3-p22.1, 8q24.3, 9q33.3-q34.3, 11p11.2, 11q12.2-q13.3, 
11q23.3, 12p13.31, 14q11.2-q12, 16p13.3-p11.2, 16q24.3, 17q12, 17q21.2-q21.31, 
19p13.3-p12, 19q13.11-q13.42, 20p13-p12.3, Xq28.
Losses:
1q21.3, 4p13-p12, 4q26-q27, 8p22, 6p21.2-p21.1, 13q33.1-q33.3, 14q12, 
16p13.3-p13.2, 17q11.2-q12, 18q11.2-q23, 19p13.3.
Capsular invasion 
S9
S10
S11
S12
S13
3.0
6.5
2.0
4.0
10.0
N/A
9 (5+4)
6 (3+3)
4 (2+2)
5 (3+2)
T3N0M0
T3N0M0
T3N0MX
T3N0M0
T4N0M1
Gains:
1q23.3, 2q35, 3q29, 4p14, 6p25.2, 8q24.3, 9q34.11, 11p15.4, 11q23.3, 12p13.31, 
16p11.2, 16p13.3, 16q24.3, 17q12, 17q21.2-q21.21, 19p13.3, 20p13-p12.3, Xq28.
Losses:
3q26.31, 5q31.1, 12q13.13, 14q24.2, 16p13.3, 17q12, 19p13.3, 22q13.1.
Metastasis
S14
S15
S16
S17
S18
S19
S20
S21
S22
S23
S24
S25
S26
S27
10.0
4.0
6.0
7.5
6.0
4.5
2.0
3.5
6.0
3.0
6.0
4.0
4.0
4.5
7 (3+4)
8 (3+5)
7 (3+4)
9 (5+4)
7 (4+3)
9 (4+5)
9 (5+4)
8 (4+4)
9 (4+5)
8 (5+3)
7 (3+4)
8 (4+4)
9 (5+4)
9 (5+4)
T4N0M1
T4N0M2
T4N0M1
T4N0M1
T4N0M1
T4N0M1
T4N0M1
T4N0M2
T4N0M3
T4N0M4
T4N0M5
T3N0M1
T4N0M1
T1N1M1
Gains: 
1p36.11-p35.3, 1q32.1, 2p11.2-2q35, 3q29, 4p14, 5q31.1, 6q25.1, 7q22.1, 8q24.3, 
9p22.1, 10q21.3-q22.2, 11q23.3, 12p13.31, 14q24.2-q24.3, 15q15.1, 16p11.2, 17q12, 
20p13-p12.3, 22q13.1, Xq28.
Losses: 
1q21.3, 3p13-p11.2, 3q26, 4p13-p12, 4q26-q27, 5q31.1-q31.2, 6p21.2-p21.1, 
7q21.1-q21.3, 8p21.2, 11p15.4, 12q13.13, 13q33.1-q33.3, 14q12, 16p13.3-p13.2, 
17q11.2-q12, 18q11.2-q23, 19p13.3.
Cases with non-recorded tumour stage
S28
S29
S30
S31
S32
S33
S34
S35
S36
4.0
7.0
6.0
6.0
7.5
3.5
3.0
4.0
5.0
9 (4+5)
8 (5+3)
8 (5+3)
8 (4+4)
8 (4+4)
7 (3+4)
10 (5+5)
9 (4+5)
7 (3+4)
-
-
-
-
-
-
-
-
-
Gains:
2q35, 4p14, 6q25.1, 7p22.3-p22.1, 8q24.3, 11q23.3, 12p13.31, 14q24.2-q24.3, 
16q22.1, 22q13.1, Xq28.
Losses:
1q21.3, 12q13.13, 17q21.33-q22, 18q11.2-q23.
   
* Aberration’s were defined by log2 ratio of 0.25 for chromosomal gains and -0.25 for chromosomal losses. The bold chromosome arms showed the aberrant chromosomal 
regions shared by each group
 
frequent deletion of myopodin gene was also reported 
and this was shown to correlate with prostate cancer 
aggressiveness (Sanchez-Carbayo et al. 2003; Yu & Luo 
2006; Yu et al. 2006). In our study, 4q26-q27 minimal 
deleted region containing myopodin gene, was detected 
in 27 (75%) out of 36 cases. Of the 27 cases, deletion 
of myopodin was found in all organ-confined prostate 
cancer (29.6%), 7.4% in prostate cancer with capsular 
invasion while 37% of cases showed distant metastases. 
We postulated that the deletion of myopodin might be 
involved in the progression of prostate cancers from early 
to advanced stages. However, no significant correlation 
between myopodin deletion and clinicopathological 
parameters was found. 
 We noted a loss of 13q33.1-q33.3 at a relatively 
high frequency, observed in 25 (69.4%) out of 36 cases. 
This region includes the ERCC5 gene. ERCC5 is the DNA 
repair gene, which is one of the vital components of DNA 
repair mechanisms in nucleotide excision repair (NER) 
pathway. Previous analyses have suggested that several 
polymorphisms in the coding sequence of the ERCC5 
gene were associated with an increased risk of some 
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cancers, such as lung (Kiyohara & Yoshimasu 2007) and 
bladder cancer (Sanyal et al. 2004). Other study found 
no significant association of ERCC5 gene with the risk of 
prostate cancer (Hooker et al. 2007) whereas recent study 
found a significant association of this gene with prostate 
cancer risk due to the combined effect with other NER 
genes (Berhane et al. 2012). Despite that, ERCC5 gene 
was reported for having loss of heterozygosity (LOH) in 
prostate cancer, concluded that this gene is important 
in the development of prostate cancer. In our study, 
the ERCC5 gene was found to be deleted and showed 
significant correlation with high Gleason grade (p=0.017). 
To the best of our knowledge, this is the first study 
showing deletion of ERCC5 gene in a series of prostate 
cancer.
 Loss of 3p was also noted, with the minimal 
deleted region detected at 3p13-p11.2. We have found 
that deletion of 3p13-p11.2 region showed significant 
correlation with high Gleason grade. One of the genes 
affected in this region is ROBO1, a gene which encodes 
a transmembrane receptor. ROBO1 was found to interact 
with SLIT1 protein during development of the nervous 
system (Andrews et al. 2007). Previous study showed that 
ROBO1 expression was significantly decreased in prostate 
tumors compared to normal prostate (Latil et al. 2003). 
High ROBO1 expression was also detected in endometrial 
TABLE 2. Most frequent regions of gains and losses detected by array CGH in 36 prostate adenocarcinomas by ethnicity
Ethnic 
group
Total 
(n=36)
(%) Chromosomal aberrations
Gains Losses
Malay 29 81% 1q32.1, 2p11.2, 3p14.3, 4q31.1, 5q35, 
6p21.3, 7q36.1, 8q24.2, 8q21.1, 8q24.3, 
9q34.1, 10q21.3, 10q22.2, 11q13.3, 
12p13.31, 13q12.11, 14q11.2-q12, 15q24, 
16q24.3, 17q12, 18q21.3, 19q13.33, 
20p13-p12, 21q22.3, Xq12.
1q21.3, 2p13.1 - p11.2, 3p13 - p11.2, 4q25, 
5q31.1-q31.2, 5q31.1-q31.2, 6q15-q16.1, 
17q21.2-q22, 8p22, 9p22.1-p21.2, 10q23, 
10q25.1-q25.2, 13q33.1, 14q12, 15q21, 
17p12, 18q11.2.
Chinese 6 17% 1q32.1, 2q11.2, 3q29, 4p14, 5q31.1, 6q25.1, 
7q36.1, 8q24.2, 9p22.1, 10q22.2, 11q13.3, 
12p13.31, 14q11.2-q12, 16q24.3, 17q12, 
19q13.33, Xq12.
1q21.3,  2q24,  3q11.2-q13.3,  4q25 , 
5p14.1-p13.3, 6q15-q16.1, 7q21.11 - 
q21.3, 8p22, 9p22.1-p21.2, 10q23.2-q23.3, 
12q13.31, 13q33.1, 14q12, 16p13, 17q11, 
17q11.2-q12, 18q11.2-q23. 
Others 1 3% 2q24.3-q35, 3q22.2-q27.1, 6q11.1-q24.1, 
7q11.23-q31.11, 12q15-q23.2, 14q12-q23.1, 
17q12, Xq12.
1p36.3-p35.3, 1q32.1, 3p21.1, 4p16.3-p15.3, 
4q25, 5p15.33, 6q27, 8q24.22-q24.3, 9q34, 
10q11.2-q26.3, 11p15, 11q12-q13, 12q13.1, 
13q34, 15q23-q26, 16p13.3, 16q23-q24, 
17q25, 19p13.3-p12, 19q13.2, 20q13.33, 
21q22. 22q13.33.
* The bold chromosome arms showed the aberrant chromosomal regions shared by each ethnic group
    
TABLE 3. Most frequent regions of losses detected by array CGH in 36 prostate adenocarcinomas 
and the list of genes contained in the affected area
Aberrant regions Genes contained in the regions Number of cases (%)
2q13.2-q14.3 GLI2, TFCP2L1, CLASP1, RNU4ATAC, MKI67IP, TSN, CNTNAP5, GYPC, BIN1... 7 (19.4)
3p13-p11.2 CNTN3, FAM86D, FRG2C, ZNF717, ROBO2, ROBO1, GBE1, CADM2, CHMP2B, POU1F1... 8 (22.2)
4q26-q27  TRAM1L1, NDST3, SNHG8, PRSS12, CEP170L, METTL14, SEC24D, SYNPO2, MYOZ2, 
FABP2..
27 (75.0)
6q15-q16.1 MAP3K7, EPHA7, TSG1, MANEA, FUT9... 27 (75.0)
8p22 SGCZ, TUSC3, MSR1, FGF20, EFHA2.. 22 (61.1)
8p21.2 SLC25A37, NKX3-1, NKX2-6, STC1.. 13 (36.1)
10q23.2-q23.31 PTEN, LIPM, ANKRD22, STAMBPL1, ACTA2, FAS.. 17 (47.2)
12p13.33-p13.31 PRMT8, PARP11, CCND2, AKAP3, NDUFA9, GALNT8, KCNA6, NTF3.. 5 (13.9)
13q33.1 FGF14, TPP2, KDELC1, BIVM, ERCC5, SLC10A2, DAOA, EFNB2, ARGLU1, LIG4.. 25 (69.4)
18q11.2-q23 MC4R, CDH20, RNF152, PIGN, ZCCHC2, PHLPP, BCL2, KDSR.. 19 (52.8)
17p12 RICH2, ELAC2, HS3ST3A1, CDRT15P, COX10, CDRT15, PMP22, TEKT.. 8 (22.2)
*Several known oncogenes, tumour suppressor genes as well as potential genes were shown in bold
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TABLE 5. Specific regions that significantly correlated with clinicopathological parameters
Clinicopathological parameter Aberrant regions p-value
Tumor size (cm)
16q24.3 gain
+ -
 <4.5
 ≥4.5
 7 (36.8)
12 (63.2)
19/36 (52.8)
13 (76.5)
 4 (23.5)
17/36 (47.2)
0.023
Gleason grade
6q25.1 gain
+ -
< Gleason 7
≥ Gleason 7
 0 (0.0)
18 (100.0)
18/36 (50.0)
 5 (29.4)
12 (70.6)
17/36 (47.2)
0.019
Gleason grade
Xq12 gain
+ -
< Gleason 7
≥ Gleason 7
 3 (42.9)
 4 (57.1)
7/36 (19.4)
2 (7.1)
26 (92.9)
28/36 (77.8)
0.044*
Gleason grade
3p13-p11.2 loss
+ -
< Gleason 7
≥ Gleason 7
3 (42.9)
4 (57.1)
7/36 (19.4)
2 (7.1)
26 (92.9)
28/36 (77.8)
0.044*
Gleason grade
13q33.1 loss
+ -
< Gleason 7
≥ Gleason 7
1 (4.0)
24 (96.0)
25/36 (69.4)
4 (40.0)
6 (60.0)
10/36 (27.8)
0.017
Metastasis 12p13.31 gain
+ -
Bone
Other site
No metastasis
11 (68.8)
 0 (0.0)
 5 (31.2)
16/36 (44.4)
1 (25.0)
2 (50.0)
1 (25.0)
4/36 (11.1)
0.043
* Fisher Exact’s test
TABLE 4. Most frequent regions of gains detected by array CGH in 36 prostate adenocarcinomas 
and the list of genes contained in the affected area
Aberrant regions Genes contained in the regions Number of cases (%)
7q36.1 EZH2, PDIA4, ZNF786, ZNF425, ZNF398, ZNF398, ZNF282, ZNF212... 19 (52.8)
8q23.3-q24.1 PKHD1L1, EBAG9, GOLSYN, KCNV1, CSMD3, TRPS1, EIF3H.. 10 (27.8)
8q24.2  SQLE, KIAA0196, NSMCE2, TRIB1, FAM84B, POU5F1P1, POU5F1B, LOC727677, MYC, 
PVT1...
 9 (25.0)
8q21.1 TSNARE1, BAI1, ARC, JRK, PSCA, LY6K, C8orf55, SLURP1, LYPD2..  8 (22.2)
8q24.3 RPL7, RDH10, STAU2, UBE2W, TCEB1, TMEM70, LY96, JPH1..  8 (22.2)
11q13.3 MYEOV, CCND1, ORAOV1, ANO1, FADD, PPFIA1, CTTN, SHANK2, DHCR7, NADSYN1.. 26 (72.2)
12p13.31 CD9, PLEKHG6, TNFRSF1A, SCNN1A, LTBR, SRP14P1, LOC678655, CD27, TAPBPL, 
VAMP1, MRPL51, NCAPD2, SCARNA10, GAPDH..
27 (75.0)
16q24.3 ANKRD11, SPG7, RPL13, CPNE7, DPEP1, CHMP1A, C16orf55, CDK10, SPATA2L, FANCA.. 19 (52.8)
17q12 PPP1R1B, STARD3, TCAP, PNMT, PERLD1, HER2, GRB7.. 31 (86.1)
Xq12  AR, OPHN1.. 7 (19.4)
*Several known oncogenes, tumour suppressor genes as well as potential genes were shown in bold
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cancer and in patients with recurrent endometrial cancer 
in contrast to those without recurrence (Ma et al. 2010). 
Deletion at 3p mapping to this gene was also frequent 
in other cancer including lung cancer (Lerman & Minna 
2000). 
CHROMOSOMAL GAINS
A gain at 17q was the most frequent chromosomal gain 
in our study, with a minimal region occurring at 17q12, 
the region in which the oncogene HER2 is located. We 
have detected HER2 amplification in 31 out of 36 (86.1%) 
cases, however this was not statistically significant when 
correlated with the clinicopathological parameters. The role 
of HER2 in prostate cancer remains controversial (Bubendorf 
et al. 1999; Ross et al. 1997), although amplification of 
HER2 is frequently found in breast cancers. The frequency 
of 17q12 amplified region found in our study was slightly 
higher than that in other studies.
 A gain of 12p13.31 was also detected in our cases. 
This region showed significant correlation with bone 
metastases. One of the genes contain in this region is 
CD9. CD9 gene encodes the protein that belongs to the 
tetraspanins family, which involved in many cellular 
processes including differentiation, adhesion and signal 
transduction. CD9 has been implicated in various tumor 
types such as colon (Hashida et al. 2003), pancreatic (Sho 
et al. 1998) and bladder cancer (Mhawech et al. 2003) and 
loss of CD9 expression was suggested to be one of the steps 
that promote cancer progression in most cases analyzed. 
However, in prostate cancer, CD9 did not appear to affect 
tumorigenesis in vivo (Zvieriev et al. 2005). In our study, 
we detected the gain of CD9 (12p13.31) in 16 cases and 11 
(68.8%) of these showed bone metastases. This suggests 
the role of this gene in the behaviour of tumor progression 
to metastasis.
 Gain of 16q was detected in our cases with minimal 
region of gains at 16q24.3, observed in 19 (52.8%) out 
of 36 cases. This region showed significant correlation 
with tumor size (>4.5 cm). CDK10 gene is one of the genes 
contain in this region. CDK10 (cyclin-dependent kinase 10) 
is a member of Cdc2-related kinases family that plays a role 
of the G2/M phase transition in the cell cycle (Zvieriev et 
al. 2005). This gene was reported to be implicated in breast 
cancer however the gain of this gene in prostate cancer 
has not been reported in previous studies. Our study also 
showed that CDK10 was more frequent in cases with bone 
metastasis (7/19; 36.8%), suggesting that this gene may 
have a possible involvement in prostate tumor progression, 
although no significant correlation was found.
 Array CGH also detected amplification at Xq12 in 
our cases (7/36; 19%), the region in which the androgen 
receptor (AR) gene is located. However, our findings were at 
lower frequencies than those found in previous studies. We 
found that Xq12 amplified region correlated significantly 
with high tumor grade (>Gleason 7). Previous study had 
demonstrated that AR gene seems to be rarely amplified in 
primary tumors (Bubendorf et al. 1999) while other study 
found that AR gene was amplified in 20–50% of hormone-
refractory prostate cancers (Brown et al. 2002). Despite 
the amplification at the Xq12 region, a frequent Xq28 
amplification was also noted in our cases but at fairly 
low frequencies, in line with the finding of previous study 
which identified the second cancer susceptibility locus 
on Xq27-q28, suggests that there might be also other 
genes on chromosome X may involve in the prostate 
tumorigenesis. 
 In summary, array CGH analysis of a series of 36 
prostate adenocarcinomas identified deleted and amplified 
chromosomal aberrant regions, some of which correlated 
with clinicopathological parameters. We also found no 
significant chromosomal aberration according to racial 
distribution as the number of each races analysed wasn’t 
equally proportioned. Future study on larger series of 
prostate cancer patients would be of valuable data to 
correlate the chromosomal aberrations according to 
race. Several genes within the aberrant chromosomal 
sites such as myopodin (4q26-q27), ROBO1 (3p13-p11.2), 
ERCC5 (13q33.1-q33.3) and CD9 (12p13.31) have not been 
reported in previous array CGH studies. Our array CGH 
profile may provide important clues in identifying putative 
genes within these altered regions. Our chromosomal 
aberration results deserve further evaluation of these 
genes on their role in prostate tumorigenesis of Malaysian 
population. 
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